Opus Genetics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Opus Genetics, Inc. (IRD) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-57.53-9.9917.89-56.69-24.62
Depreciation & Amortization0.010.010.000.000.01
Stock Based Compensation3.363.511.811.911.51
Change in Working Capital3.094.08-5.560.181.15
Change in Accounts Receivable-3.442.52-4.850.000.00
Change in Accounts Payable0.221.08-0.520.380.79
Change in Other Working Capital6.310.48-0.19-0.200.35
Other Operating Activities-2.521.250.0035.153.72
Net Cash from Operating Activities-25.58-1.1114.31-19.37-6.80
Investing Activities
Capital Expenditures0.000.000.00-0.10-1.48
Acquisitions0.000.000.000.002.01
Other Investing Activities1.210.000.000.000.00
Net Cash from Investing Activities1.210.000.00-0.100.54
Financing Activities
Debt Repayment0.000.00-0.54-0.110.00
Common Stock Issued4.509.264.4328.580.06
Common Stock Repurchased-0.080.000.000.000.00
Other Financing Activities-0.23-0.28-0.13-1.5118.87
Net Cash from Financing Activities4.198.983.7927.6121.12
Summary
Net Change in Cash-20.187.8718.108.1414.86
Cash at Beginning of Period50.5042.6324.5316.400.00
Cash at End of Period30.3250.5042.6324.530.00
Free Cash Flow-25.58-1.1114.31-19.47-8.27
Supplemental Disclosures
Interest Paid0.000.000.010.000.00
Income Taxes Paid0.000.340.000.000.00